Announced positive Phase 1 data for SION-719 and SION-451 demonstrating both first-in-class NBD1 stabilizers were generally ...

Compugen advances COM701 in ovarian cancer with strong partners, key catalysts ahead, and funding into 2027. Find out why ...

Globalstar (NASDAQ: GSAT), a next-generation telecommunications infrastructure and technology provider, and Parsons Corporation, a global leader in national security and critical infrastructure ...

The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced ...

ABCL-575’s predicted dosing schedule of every six months is enabled by a "human half-life of approximately 67 days," as ...

We are pleased with the progress we’ve made this past quarter, underscored by the encouraging tolerability and PK data from the Phase 1 trials of ...

If approved, Novartis' ianalumab would become the first targeted treatment for patients with Sjögren’s disease.

GAAP net loss per share was $(11.29) for Q2 2025, missing the consensus GAAP EPS estimate of $(4.62) by a wide margin, mainly due to a $17.0 million up-front license fee. NextCure advanced both its ...

An ankle sprain on Mars? An earache on the Moon? NASA and Google are building a proof-of-concept AI medical assistant ...

The round was led by Valour Capital and Chhattisgarh Investments Limited, early-stage investors focused on deep-tech/energy ...

In April 2025, Monte Rosa presented preclinical data on the potential of its highly selective CDK2-directed molecular glue degrader, MRT-51443, to treat HR-positive/HER2-negative breast cancer at the ...